# Bioequivalence Study of Albendazole 400 mg Tablets in Chinese Population

> **NCT01755637** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 56 (actual)

## Conditions studied

- Helminthiasis

## Interventions

- **DRUG:** Albendazole

## Key facts

- **NCT ID:** NCT01755637
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2012-04
- **Final completion:** 2012-06
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2013-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01755637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01755637, "Bioequivalence Study of Albendazole 400 mg Tablets in Chinese Population". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01755637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*